Join
Live feed
·
PRReleasevia Quantisnow
ZyVersa Therapeutics Inc. logo

ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)

ByQuantisnow·Wall Street's wire, on your screen.
ZVSA· ZyVersa Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZVSA (ZyVersa Therapeutics Inc.) and more on Quantisnow.